Latest news and press releases about Immutep Limited (IMMP): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers.
Price
| Price | $0.33 |
| Market Cap | $48M |
| Exchange | NASDAQ |
| Country | AU |
Valuation Ratios
| Price / Book | 1.03 |
| EV / EBITDA | -0.26 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -126.06% |
| Return on Invested Capital | -118.22% |
| Return on Assets | -93.15% |
| Gross Margin | 84.97% |
| Operating Margin | -597.44% |
| Net Margin | -544.79% |
Related companies: ACHV · ALLO · CABA · CADL · CAPR · EDIT · MREO
Explore sector: Healthcare · Biotechnology
More sections of IMMP: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks